Glycoprotein hormone alpha-subunit secretion in patients with pituitary adenomas: influence of TRH, LRH and bromocriptine.
dc.contributor.author | MacFarlane, I A | |
dc.contributor.author | Beardwell, Colin G | |
dc.contributor.author | Shalet, Stephen M | |
dc.contributor.author | Ainslie, Gill | |
dc.contributor.author | Rankin, Elaine M | |
dc.date.accessioned | 2011-05-31T14:36:57Z | |
dc.date.available | 2011-05-31T14:36:57Z | |
dc.date.issued | 1982-04 | |
dc.identifier.citation | Glycoprotein hormone alpha-subunit secretion in patients with pituitary adenomas: influence of TRH, LRH and bromocriptine. 1982, 99 (4):487-92 Acta Endocrinol. | en |
dc.identifier.issn | 0001-5598 | |
dc.identifier.pmid | 6803489 | |
dc.identifier.doi | 10.1530/acta.0.0990487 | |
dc.identifier.uri | http://hdl.handle.net/10541/132365 | |
dc.description.abstract | Twelve patients with pituitary adenomas and increased serum concentration of the glycoprotein hormone alpha-subunit were studied. Eight patients were acromegalic and one had a FSH producing tumour. The adenomas in 9 patients had undergone subtotal operative removal and/or external irradiation but no patient was studied within 3 months of these treatments. Many of the acromegalic patients, with moderately elevated alpha-levels, showed marked increases in alpha-concentration after TRH and/or LRH, compared with controls. The non-acromegalic patients, with the highest alpha-levels, showed poor responses to releasing hormones. These results suggest that excessive alpha-subunit secretion in acromegalic patients is often under hypothalamic control whereas in non-acromegalic patients it is often autonomous. Seven patients, 4 with acromegaly, were then given oral bromocriptine, 5 mg over 3 h. There was a significant fall in log mean alpha-level at 4 and 5 h (P less than 0.02). Six patients took bromocriptine for 1--2 months. Log mean alpha-concentration was significantly reduced at the end of treatment (P less than 0.02) and then recovered to basal levels after stopping treatment for one week. alpha-Subunit hypersecretion in some patients with pituitary adenomas is therefore modulated by dopaminergic control mechanisms. | |
dc.language.iso | en | en |
dc.subject.mesh | Acromegaly | |
dc.subject.mesh | Adenoma | |
dc.subject.mesh | Bromocriptine | |
dc.subject.mesh | Female | |
dc.subject.mesh | Glycoproteins | |
dc.subject.mesh | Gonadotropin-Releasing Hormone | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Pituitary Neoplasms | |
dc.subject.mesh | Receptors, Dopamine | |
dc.subject.mesh | Thyrotropin-Releasing Hormone | |
dc.title | Glycoprotein hormone alpha-subunit secretion in patients with pituitary adenomas: influence of TRH, LRH and bromocriptine. | en |
dc.type | Article | en |
dc.identifier.journal | Acta Endocrinologica | en |
html.description.abstract | Twelve patients with pituitary adenomas and increased serum concentration of the glycoprotein hormone alpha-subunit were studied. Eight patients were acromegalic and one had a FSH producing tumour. The adenomas in 9 patients had undergone subtotal operative removal and/or external irradiation but no patient was studied within 3 months of these treatments. Many of the acromegalic patients, with moderately elevated alpha-levels, showed marked increases in alpha-concentration after TRH and/or LRH, compared with controls. The non-acromegalic patients, with the highest alpha-levels, showed poor responses to releasing hormones. These results suggest that excessive alpha-subunit secretion in acromegalic patients is often under hypothalamic control whereas in non-acromegalic patients it is often autonomous. Seven patients, 4 with acromegaly, were then given oral bromocriptine, 5 mg over 3 h. There was a significant fall in log mean alpha-level at 4 and 5 h (P less than 0.02). Six patients took bromocriptine for 1--2 months. Log mean alpha-concentration was significantly reduced at the end of treatment (P less than 0.02) and then recovered to basal levels after stopping treatment for one week. alpha-Subunit hypersecretion in some patients with pituitary adenomas is therefore modulated by dopaminergic control mechanisms. |